BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Rheumatoid Arthritis
In brief
This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who have previously had an inadequate response to treatment with anti-tumor necrosis factor (anti-TNF) therapy.
Key facts
- Study ID
- NCT00458861
- Run by
- Biogen
- People needed
- 115
- Starts
- 2007-03-01
- Expected to finish
- 2008-10-01
- Last updated by the study team
- 2016-01-21
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University — Palo Alto, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.